N/A
Completed N=34
Long-term Effect of Lanthanum Carbonate on Bone
Hyperphosphatemia
Source: ClinicalTrials.gov NCT00557323 ↗
Enrolled (actual)
34
Serious AEs
52.9%
Results posted
Jun 2011
Primary outcomePrimary: Number of Study-emergent Bone-related Adverse Events (AEs) — 9; 2; 1; 1 Bone-related AEs
Summary
Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an additional 5 years. Patients were being observed for any bone adverse events or other serious adverse events, as well as the collection of mortality data.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Study-emergent Bone-related Adverse Events (AEs) |
9; 2; 1; 1; 1; 1 | — |
| SECONDARY Number of Study-emergent Deaths |
3 | — |
Eligibility Criteria
Inclusion Criteria
- Any patient who had exposure to lanthanum carbonate in SPD405-309
Data sourced from ClinicalTrials.gov (NCT00557323). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.